Lactobacillus rhamnosus GG
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07643974 | Jun 2026 → Sep 2027 expected | multiple sclerosis, spina bifida, spinal cord injury, urinary bladder disorder +1 | Medstar Health Research Institute | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00748748 | Feb 2010 → Apr 2012 | diarrheal disease | Fargo VA Medical Center | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07102836 | Aug 2025 → Feb 2026 overdue | hyperbilirubinemia | Quaid-e-Azam Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05230511 | Jun 2022 → Jul 2026 overdue | spinal cord injury | Medstar Health Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04150380 | Aug 2020 → Dec 2025 | post-traumatic stress disorder | VA Eastern Colorado Health Care System | Completed | No outcome recorded |
| Phase 2 | NCT02748356 | Jan 2016 → Oct 2018 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02748317 | Jan 2016 → Oct 2018 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT01773967 | Jul 2014 → Aug 2018 | gastroenteritis | Washington University School of Medicine | Completed | Missed primary |
| Phase 2/3 | NCT00445120 | Mar 2007 → Sep 2008 | vernal keratoconjunctivitis | Campus-Bio-Medico University | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT03032354 | Jul 2017 → Dec 2018 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | Missed primary |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT07270159 | Jun → Oct 2025 | periapical periodontitis, pulpitis | Dow University of Health Sciences | Completed | No outcome recorded |
| — | NCT05165329 | Nov 2021 → Sep 2024 | food allergy | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT00159523 | Dec 2003 → Sep 2007 | asthma, atopic eczema, perennial allergic rhinitis | Norwegian University of Science and Technology | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00756262 Comparator | Mar 2003 → Jul 2012 | — | Tufts Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT07296718 Comparator | May → Nov 2023 | neonatal sepsis, perinatal necrotizing enterocolitis | Madiha, MPhil | Completed | No outcome recorded |
| — | NCT02807246 Comparator | Dec 2014 → Dec 2015 | hyperbilirubinemia | Karadeniz Technical University | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus rhamnosus GG | “Participants received a 5-day course of Lactobacillus rhamnosus GG at a dose of 1×1010 colony-forming units twice daily or matching placebo.” PMID 30462938 ↗ Nov 201815“The probiotic milk contained Lactobacillus rhamnosus GG, L. acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12.” PMID 20545688 ↗ Jun 2010 “probiotic Lactobacillus rhamnosus GG (LGG) for the reduction or elimination of intestinal colonization by VRE.” PMID 26014940 ↗ May 2015 “PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder.” NCT05165329 ↗ “Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey” NCT02807246 ↗ “a probiotic paste consisting of Lactobacillus rhamnosus GG” NCT07270159 ↗ “10\^10 Lactobacillus rhamnosus GG per capsule” NCT00748748 ↗ “Lactobacillus rhamnosus GG” NCT02748356 ↗ |
| Known as | ATCC strain 53103 | “Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)” NCT04150380 ↗ |
| Known as | CRMTS #11272 | “Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)” NCT04150380 ↗ |
| Known as | Culturelle | “Lactobacillus GG or Culturelle” NCT00756262 ↗ |
| Known as | Culturelle GG | “Participants will receive the Lactobacillus (Culturelle GG, 20 billion live organisms for adults and 10 billion live organisms for children \<18 years of age)” NCT02748356 ↗ |
| Known as | LGG | “Here we present the methods of a large, rigorous, randomised, double-blind placebo-controlled study to assess the effectiveness and side effect profile of Lactobacillus...” PMID 28947466 ↗ Sep 20172“The probiotic bacteria included Lactobacillus rhamnosus GG (LGG), Bifidobacterium animalis subsp. lactis Bb-12 and Lactobacillus acidophilus La-5.” PMID 28837002 ↗ Aug 2017 “Lactobacillus rhamnosus GG (LGG; ATCC53103), a probiotic shown to have anti-inflammatory and immunoregulatory effects” NCT04150380 ↗ |
| Known as | PTS #3766 | “Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)” NCT04150380 ↗ |
| Modality | Other / unclassified | “The probiotic bacteria included Lactobacillus rhamnosus GG (LGG), Bifidobacterium animalis subsp. lactis Bb-12 and Lactobacillus acidophilus La-5.” PMID 28837002 ↗ Aug 2017 |
| Route | Oral | “a subset of 278 pregnant mothers was randomized to drink milk with or without probiotic bacteria during and after pregnancy” PMID 33240830 ↗ Nov 2020 |